Literature DB >> 29127619

Changes in the lung bacteriome in relation to antipseudomonal therapy in children with cystic fibrosis.

Lenka Kramná1, Pavel Dřevínek2, Jake Lin3, Michal Kulich4, Ondrej Cinek5.   

Abstract

The lung in cystic fibrosis (CF) is home to numerous pathogens that shorten the lives of patients. The aim of the present study was to assess changes in the lung bacteriome following antibiotic therapy targeting Pseudomonas aeruginosa in children with CF. The study included nine children (9-18 years) with CF who were treated for their chronic or intermittent positivity for Pseudomonas aeruginosa. The bacteriomes were determined in 16 pairs of sputa collected at the beginning and at the end of a course of intravenous antibiotic therapy via deep sequencing of the variable region 4 of the 16S rRNA gene, and the total bacterial load and selected specific pathogens were assessed using quantitative real-time PCR. The effect of antipseudomonal antibiotics was observable as a profound decrease in the total 16S rDNA load (p = 0.001) as well as in a broad range of individual taxa including Staphylococcus aureus (p = 0.03) and several members of the Streptococcus mitis group (S. oralis, S. mitis, and S. infantis) (p = 0.003). Improvements in forced expiratory volume (FEV1) were associated with an increase in Granulicatella sp. (p = 0.004), whereas a negative association was noted between the total bacterial load and white blood cell count (p = 0.007). In conclusion, the data show how microbial communities differ in reaction to antipseudomonal treatment, suggesting that certain rare species may be associated with clinical parameters. Our work also demonstrates the utility of absolute quantification of bacterial load in addition to the 16S rDNA profiling.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 29127619     DOI: 10.1007/s12223-017-0562-3

Source DB:  PubMed          Journal:  Folia Microbiol (Praha)        ISSN: 0015-5632            Impact factor:   2.099


  40 in total

Review 1.  The airway microbiome in cystic fibrosis and implications for treatment.

Authors:  Edith T Zemanick; Scott D Sagel; Jonathan K Harris
Journal:  Curr Opin Pediatr       Date:  2011-06       Impact factor: 2.856

2.  Direct sampling of cystic fibrosis lungs indicates that DNA-based analyses of upper-airway specimens can misrepresent lung microbiota.

Authors:  Amanda F Goddard; Benjamin J Staudinger; Scot E Dowd; Amruta Joshi-Datar; Randall D Wolcott; Moira L Aitken; Corinne L Fligner; Pradeep K Singh
Journal:  Proc Natl Acad Sci U S A       Date:  2012-08-07       Impact factor: 11.205

3.  Longitudinal development of mucoid Pseudomonas aeruginosa infection and lung disease progression in children with cystic fibrosis.

Authors:  Zhanhai Li; Michael R Kosorok; Philip M Farrell; Anita Laxova; Susan E H West; Christopher G Green; Jannette Collins; Michael J Rock; Mark L Splaingard
Journal:  JAMA       Date:  2005-02-02       Impact factor: 56.272

4.  Impact of antibiotic treatment for pulmonary exacerbations on bacterial diversity in cystic fibrosis.

Authors:  T W V Daniels; G B Rogers; F A Stressmann; C J van der Gast; K D Bruce; G R Jones; G J Connett; J P Legg; M P Carroll
Journal:  J Cyst Fibros       Date:  2012-06-18       Impact factor: 5.482

5.  Relative contribution of Prevotella intermedia and Pseudomonas aeruginosa to lung pathology in airways of patients with cystic fibrosis.

Authors:  Martina Ulrich; Isabelle Beer; Peter Braitmaier; Michaela Dierkes; Florian Kummer; Bernhard Krismer; Ulrike Schumacher; Ute Gräpler-Mainka; Joachim Riethmüller; Peter Ø Jensen; Thomas Bjarnsholt; Niels Høiby; Gabriel Bellon; Gerd Döring
Journal:  Thorax       Date:  2010-09-29       Impact factor: 9.139

6.  Prevalence of streptococci and increased polymicrobial diversity associated with cystic fibrosis patient stability.

Authors:  L M Filkins; T H Hampton; A H Gifford; M J Gross; D A Hogan; M L Sogin; H G Morrison; B J Paster; G A O'Toole
Journal:  J Bacteriol       Date:  2012-06-29       Impact factor: 3.490

7.  Evaluation of methods for the extraction and purification of DNA from the human microbiome.

Authors:  Sanqing Yuan; Dora B Cohen; Jacques Ravel; Zaid Abdo; Larry J Forney
Journal:  PLoS One       Date:  2012-03-23       Impact factor: 3.240

8.  Lung microbiota across age and disease stage in cystic fibrosis.

Authors:  Bryan Coburn; Pauline W Wang; Julio Diaz Caballero; Shawn T Clark; Vijaya Brahma; Sylva Donaldson; Yu Zhang; Anu Surendra; Yunchen Gong; D Elizabeth Tullis; Yvonne C W Yau; Valerie J Waters; David M Hwang; David S Guttman
Journal:  Sci Rep       Date:  2015-05-14       Impact factor: 4.379

9.  The daily dynamics of cystic fibrosis airway microbiota during clinical stability and at exacerbation.

Authors:  Lisa A Carmody; Jiangchao Zhao; Linda M Kalikin; William LeBar; Richard H Simon; Arvind Venkataraman; Thomas M Schmidt; Zaid Abdo; Patrick D Schloss; John J LiPuma
Journal:  Microbiome       Date:  2015-04-01       Impact factor: 14.650

10.  An Improved Method for High Quality Metagenomics DNA Extraction from Human and Environmental Samples.

Authors:  Satyabrata Bag; Bipasa Saha; Ojasvi Mehta; D Anbumani; Naveen Kumar; Mayanka Dayal; Archana Pant; Pawan Kumar; Shruti Saxena; Kristine H Allin; Torben Hansen; Manimozhiyan Arumugam; Henrik Vestergaard; Oluf Pedersen; Verima Pereira; Philip Abraham; Reva Tripathi; Nitya Wadhwa; Shinjini Bhatnagar; Visvanathan Gnana Prakash; Venkatesan Radha; R M Anjana; V Mohan; Kiyoshi Takeda; Takashi Kurakawa; G Balakrish Nair; Bhabatosh Das
Journal:  Sci Rep       Date:  2016-05-31       Impact factor: 4.379

View more
  1 in total

Review 1.  The Yin and Yang of Streptococcus Lung Infections in Cystic Fibrosis: a Model for Studying Polymicrobial Interactions.

Authors:  Jessie E Scott; George A O'Toole
Journal:  J Bacteriol       Date:  2019-05-08       Impact factor: 3.490

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.